(Q53131269)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

title

Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Alberto Pupi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Calogero Saieva

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

16

Giampaolo Biti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

2

Silvia Scoccianti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1

Beatrice Detti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

4

Samantha Cipressi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

Davide Franceschini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Sara Cassani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Donata Villari

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Luca Vaggelli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Maurizio Pertici

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Lorenzo Livi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

M Ceroti

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Giulio Nicita

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Marco Carini

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

publication date

27 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

Journal of Cancer Research and Clinical Oncology

18 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

volume

139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

page(s)

521-528

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography

18 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Visualization of prostate cancer with 11C-choline positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Dose-escalation using intensity-modulated radiotherapy for prostate cancer--evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Intensity-modulated radiotherapy for prostate cancer implementing molecular imaging with 18F-choline PET-CT to define a simultaneous integrated boost

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

[18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

[11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Fluorocholine PET/CT in patients with prostate cancer: initial experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Dietary choline: biochemistry, physiology, and pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1354-4

Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.

21 January 2018

1 reference

12 December 2020

Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy

1 reference

12 December 2020

Experience with carbon-11 choline positron emission tomography in prostate carcinoma

1 reference

12 December 2020

Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose

1 reference

12 December 2020

The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer

1 reference

12 December 2020

PET imaging of prostate cancer using carbon-11-choline.

1 reference

12 December 2020

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer

1 reference

12 December 2020

[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes

1 reference

12 December 2020

10.1007/S00432-012-1354-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23183655%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference